PHRM:CSE, PharmaTher Holdings Ltd.
PHRM stock overview
PharmaTher Holdings Ltd. (PHRM:CSE) closed at $0.050 on November 13, 2026,
unchanged on the day.
The stock trades 68.8% below its 52-week high of $0.160
and 11.1% above its 52-week low of $0.045.
Over the past year, it lost 64.3%.
PharmaTher Holdings Ltd. is part of the Life Sciences sector.
Key figures
- Price
- $0.050
- Day change
- 0.00%
- Volume
- 10,300
- Average volume
- 33,921
- Market cap
- 4M+
- 52-week range
- $0.045 – $0.160
- 50-day average
- $0.054
- 200-day average
- $0.064
Price action over the past year
In 252 trading sessions since November 13, 2025, PHRM closed higher on 50 days (20%).
Its best day was April 20, 2026 (+46.67%) and its worst was June 22, 2026 (-23.08%).
The stock moved 10% or more in a single session 27 times.
It opened at least 5% above the previous day's high 21 times.
Recent signals
PHRM news
-
Oct 29, 2026:
PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157
-
Oct 28, 2026:
PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency
-
Oct 7, 2026:
PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
-
Oct 5, 2026:
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
-
Oct 1, 2026:
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
-
Aug 18, 2026:
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.
Similar stocks
Find more stocks like PHRM with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.